Triple-negative breast cancer (TNBC), which accounts for 10-20% of breast cancer patients, is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [1]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.